The DOI matches its Crossref record.
Tumor Microenvironment and the Response to Anticancer Therapy
Open accessAbstract
Human solid tumors are invariably less well oxygenated than normal tissues. This leads to resistance to radiotherapy and anticancer chemotherapy, as well as predisposing for increased tumor metastases. Prolonged hypoxia of the tumor tissue also leads to necrosis, and necrotic regions are also characteristic of solid tumors. These two characteristics-hypoxia and necrosis-represent clear differences between tumors and normal tissues and are potentially exploitable in cancer treatment. This review focuses on the phenomenon of tumor hypoxia and how hypoxia and its accompanying necrosis can be exploited in therapy. One such strategy is to use drugs that are toxic only under hypoxic conditions, and the first drug of this class to enter clinical testing, tirapazamine, is showing considerable promise. The second way to exploit hypoxia is to take advantage of the selective induction under hypoxia of the transcription factor HIF-1 (hypoxia-inducible factor 1). Gene therapy strategies based on this are in development. Finally, tumor hypoxia can be exploited using live obligate anaerobes that have been genetically engineered to express enzymes that can activate non-toxic prodrugs into toxic chemotherapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tatum, J. L. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000601002324 · Cited by 620
XBP1 Is Essential for Survival under Hypoxic Conditions and Is Required for Tumor Growth
Romero-Ramirez, L., Cao, H., Nelson, D., Hammond, E., Lee, A.-H., Yoshida, H., Mori, K., Glimcher, L. H., Denko, N. C., Giaccia, A. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1606 · Cited by 570
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
Li, L., Yu, R., Cai, T., Chen, Z., Lan, M., Zou, T., Wang, B., Wang, Q., Zhao, Y., & Cai, Y. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106939 · Cited by 381
for the ‘Tumour and Angiogenesis Research Group’, Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Bougioukas, G., Didilis, V, Gatter, K. C., & Harris, A. L. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601205 · Cited by 377
A Multiscale Model for Avascular Tumor Growth
Jiang, Y., Pjesivac-Grbovic, J., Cantrell, C., & Freyer, J. P. (2005) · Biophysical Journal · doi:10.1529/biophysj.105.060640 · Cited by 372
Tumor Hypoxia in Cancer Therapy
Brown, J. M. (2007) · Methods in Enzymology · doi:10.1016/s0076-6879(07)35015-5 · Cited by 359
Self-citationThe transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Albadari, N., Deng, S., & Li, W. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1613370 · Cited by 351
Modulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors
Liu, Y., Jiang, Y., Zhang, M., Tang, Z., He, M., & Bu, W. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00214 · Cited by 307
Chang, Q., Ornatsky, O. I., Siddiqui, I., Loboda, A., Baranov, V. I., & Hedley, D. W. (2017) · Cytometry Part A · doi:10.1002/cyto.a.23053 · Cited by 300
Redox‐Active Metal Complexes for Anticancer Therapy
Zhang, P., & Sadler, P. J. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600908 · Cited by 274
Chang, Q., Jurisica, I., Do, T., & Hedley, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4049 · Cited by 272
Drug Resistance in Glioblastoma: A Mini Review
Haar, C. P., Hebbar, P., Wallace, G. C., Das, A., Vandergrift, W. A., Smith, J. A., Giglio, P., Patel, S. J., Ray, S. K., & Banik, N. L. (2012) · Neurochemical Research · doi:10.1007/s11064-011-0701-1 · Cited by 254
Yan, P., Liu, L.-H., & Wang, P. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00156 · Cited by 179
Small molecules targeting HIF-1α pathway for cancer therapy in recent years.
Tang, W., & Zhao, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115235 · Cited by 50
Murthy, A., Gerber, S. A., Koch, C. J., & Lord, E. M. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900017 · Cited by 36
Metadata
- Authors
- Brown, J. M.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2002-08-13
- Volume
- 1
- Issue
- 5
- Pages
- 453-458
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2168607632
- Cited by
- 232
- References
- 0
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.